EARLY SWITCH THERAPY APPROACH FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE

被引：0
|
作者：
Shukhov, O. [1 ]
Chelysheva, E. [1 ]
Gusarova, G. [1 ]
Abdullaev, A. [2 ]
Sudarikov, A. [2 ]
Obukhova, T. [2 ]
Turkina, A. [1 ]
机构：
[1] Sci & Advisory Dept Chemotherapy Myeloproliferat, Moscow, Russia
[2] Hlth Minist Russian Federat, Fed State Budgetary Inst Hematol Res Ctr, Moscow, Russia
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1559
引用
收藏
页码：604 / 604
页数：1
相关论文
共 50 条
  • [1] Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia
    Cortes, Jorge E.
    Jones, Dan
    O'Brien, Susan
    Jabbour, Elias
    Ravandi, Farhad
    Koller, Charles
    Borthakur, Gautam
    Walker, Brenda
    Zhao, Weiqiang
    Shan, Jianqin
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 398 - 404
  • [2] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [3] Upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
    Eskazan, Ahmet Emre
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (03) : 325 - 326
  • [4] Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question
    Sweet, Kendra
    Pinilla-Ibarz, Javier
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 103 : 99 - 108
  • [5] Optimal initial therapy for patients with newly diagnosed chronic myeloid leukemia in chronic phase
    Atallah, Ehab
    Cortes, Jorge
    CURRENT OPINION IN HEMATOLOGY, 2007, 14 (02) : 138 - 144
  • [6] Response: upfront nilotinib therapy among patients with chronic myeloid leukemia in chronic phase
    Saydam, Guray
    EXPERT OPINION ON PHARMACOTHERAPY, 2017, 18 (03) : 327 - 328
  • [7] SWITCH TO GENERIC IMATINIB: IMPACT ON MOLECULAR RESPONSES AND SAFETY IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS
    Scalzulli, E.
    Porrazzo, M.
    Stocchi, F.
    Colafigli, G.
    Molica, M.
    Diverio, D.
    Latagliata, R.
    Foa, R.
    Breccia, M.
    HAEMATOLOGICA, 2019, 104 : 22 - 23
  • [8] Radotinib in the treatment of chronic phase chronic myeloid leukemia patients
    Eskazan, Ahmet Emre
    Soysal, Teoman
    HAEMATOLOGICA, 2015, 100 (01) : E39 - E39
  • [9] Myelofibrosis in Patients of Chronic Myeloid Leukemia in Chronic Phase at Presentation
    Hamid, Ambareen
    Ashraf, Sobia
    Qamar, Samina
    Naveed, Muhammad Asif
    Hameed, Ahmad
    Farooq, Muhammad Azhar
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2019, 29 (11): : 1096 - 1100
  • [10] Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
    Cortes, Jorge E.
    Jones, Dan
    O'Brien, Susan
    Jabbour, Elias
    Konopleva, Marina
    Ferrajoli, Alessandra
    Kadia, Tapan
    Borthakur, Gautam
    Stigliano, Denise
    Shan, Jianqin
    Kantarjian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 392 - 397
12345